Literature DB >> 8865399

Bilateral subretinal neovascular membrane in idiopathic juxtafoveolar telangiectasis.

B L Lee1.   

Abstract

Entities:  

Mesh:

Year:  1996        PMID: 8865399     DOI: 10.1097/00006982-199616040-00014

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  7 in total

1.  Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration.

Authors:  B A Lafaut; S Aisenbrey; C Vanden Broecke; K U Bartz-Schmidt
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

2.  One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia.

Authors:  Nazimul Hussain; Taraprasad Das; Rohit Khanna; L S Mohan Ram; Kallukuri Sumasri
Journal:  Clin Ophthalmol       Date:  2007-12

3.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 4.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

5.  Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia.

Authors:  Pukhraj Rishi; Daraius Shroff; Ekta Rishi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-01-12       Impact factor: 3.117

6.  Large juxtafoveal telangiectasia.

Authors:  Mohammad Hossein Jabbarpour Bonyadi; Siamak Moradian
Journal:  J Ophthalmic Vis Res       Date:  2010-07

7.  Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia.

Authors:  Pukhraj Rishi; Ekta Rishi; Daraius Shroff
Journal:  Indian J Ophthalmol       Date:  2009 May-Jun       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.